RU2007120643A - METHOD FOR PREVENTION OF RECURRENCE OF CHRONIC VIRAL HEPATITIS AFTER ACHIEVEMENT OF VIROLOGICAL REMISSION - Google Patents

METHOD FOR PREVENTION OF RECURRENCE OF CHRONIC VIRAL HEPATITIS AFTER ACHIEVEMENT OF VIROLOGICAL REMISSION Download PDF

Info

Publication number
RU2007120643A
RU2007120643A RU2007120643/14A RU2007120643A RU2007120643A RU 2007120643 A RU2007120643 A RU 2007120643A RU 2007120643/14 A RU2007120643/14 A RU 2007120643/14A RU 2007120643 A RU2007120643 A RU 2007120643A RU 2007120643 A RU2007120643 A RU 2007120643A
Authority
RU
Russia
Prior art keywords
courses
recurrence
prevention
months
dose
Prior art date
Application number
RU2007120643/14A
Other languages
Russian (ru)
Other versions
RU2348412C1 (en
Inventor
Лариса Леонидовна Попова (RU)
Лариса Леонидовна Попова
Елена Александровна Мельникова (RU)
Елена Александровна Мельникова
Михаил Николаевич Смирнов (RU)
Михаил Николаевич Смирнов
Алексей Александрович Суздальцев (RU)
Алексей Александрович Суздальцев
Борис Григорьевич Перевозчиков (RU)
Борис Григорьевич Перевозчиков
Дмитрий Юрьевич Константинов (RU)
Дмитрий Юрьевич Константинов
Original Assignee
Лариса Леонидовна Попова (RU)
Лариса Леонидовна Попова
Елена Александровна Мельникова (RU)
Елена Александровна Мельникова
Михаил Николаевич Смирнов (RU)
Михаил Николаевич Смирнов
Алексей Александрович Суздальцев (RU)
Алексей Александрович Суздальцев
Борис Григорьевич Перевозчиков (RU)
Борис Григорьевич Перевозчиков
Дмитрий Юрьевич Константинов (RU)
Дмитрий Юрьевич Константинов
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лариса Леонидовна Попова (RU), Лариса Леонидовна Попова, Елена Александровна Мельникова (RU), Елена Александровна Мельникова, Михаил Николаевич Смирнов (RU), Михаил Николаевич Смирнов, Алексей Александрович Суздальцев (RU), Алексей Александрович Суздальцев, Борис Григорьевич Перевозчиков (RU), Борис Григорьевич Перевозчиков, Дмитрий Юрьевич Константинов (RU), Дмитрий Юрьевич Константинов filed Critical Лариса Леонидовна Попова (RU)
Priority to RU2007120643/14A priority Critical patent/RU2348412C1/en
Publication of RU2007120643A publication Critical patent/RU2007120643A/en
Application granted granted Critical
Publication of RU2348412C1 publication Critical patent/RU2348412C1/en

Links

Abstract

Способ профилактики рецидива хронического вирусного гепатита С после достижения первичной вирусологической ремиссии с помощью стандартной интерфероновой терапии, отличающийся тем, что после интерферонотерапии применяют Ронколейкинв дозе 500 мг внутрь в 200 мл воды через 2 ч после ужина, двумя курсами по 5-10 раз через день или 2 раза в неделю, после третьего приема препарата Ронколейкинбольной принимает Ликопид 10 мг ежедневно 1 раз в день в течение 10 дней, интервал между курсами 2 месяца, осуществляя контроль общего анализа крови, функциональных проб печени 1 раз в месяц и иммунограммы 1 раз в 3 месяца, при необходимости курсы лечения повторяются весной и осенью.A method for the prevention of recurrence of chronic viral hepatitis C after achieving primary virological remission using standard interferon therapy, characterized in that after interferon therapy, a dose of 500 mg Roncoleukin is used orally in 200 ml of water 2 hours after dinner, in two courses of 5-10 times every other day or 2 times a week, after the third dose of the drug, Roncoleukin patient takes Likopid 10 mg daily 1 time per day for 10 days, the interval between courses is 2 months, monitoring the general blood test, functionally liver samples 1 time per month and immunograms 1 time in 3 months, if necessary, treatment courses are repeated in spring and autumn.

Claims (1)

Способ профилактики рецидива хронического вирусного гепатита С после достижения первичной вирусологической ремиссии с помощью стандартной интерфероновой терапии, отличающийся тем, что после интерферонотерапии применяют Ронколейкин® в дозе 500 мг внутрь в 200 мл воды через 2 ч после ужина, двумя курсами по 5-10 раз через день или 2 раза в неделю, после третьего приема препарата Ронколейкин® больной принимает Ликопид 10 мг ежедневно 1 раз в день в течение 10 дней, интервал между курсами 2 месяца, осуществляя контроль общего анализа крови, функциональных проб печени 1 раз в месяц и иммунограммы 1 раз в 3 месяца, при необходимости курсы лечения повторяются весной и осенью.A method for the prevention of recurrence of chronic viral hepatitis C after achieving primary virological remission using standard interferon therapy, characterized in that after interferon therapy, Roncoleukin ® is used at a dose of 500 mg orally in 200 ml of water 2 hours after dinner, in two courses of 5-10 times every day or 2 times a week, after the third dose of the drug Roncoleukin ®, the patient takes Likopid 10 mg daily 1 time per day for 10 days, the interval between courses is 2 months, monitoring the general blood test, function liver samples 1 time per month and immunograms 1 time in 3 months, if necessary, treatment courses are repeated in spring and autumn.
RU2007120643/14A 2007-06-01 2007-06-01 Method of prevention of chronic viral hepatitis type c recurrent after virus remission RU2348412C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2007120643/14A RU2348412C1 (en) 2007-06-01 2007-06-01 Method of prevention of chronic viral hepatitis type c recurrent after virus remission

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2007120643/14A RU2348412C1 (en) 2007-06-01 2007-06-01 Method of prevention of chronic viral hepatitis type c recurrent after virus remission

Publications (2)

Publication Number Publication Date
RU2007120643A true RU2007120643A (en) 2008-12-10
RU2348412C1 RU2348412C1 (en) 2009-03-10

Family

ID=40528526

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007120643/14A RU2348412C1 (en) 2007-06-01 2007-06-01 Method of prevention of chronic viral hepatitis type c recurrent after virus remission

Country Status (1)

Country Link
RU (1) RU2348412C1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2515941A (en) 2011-10-21 2015-01-07 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
EA201490836A1 (en) 2011-10-21 2014-11-28 Эббви Инк. COMBINATION TREATMENT (FOR EXAMPLE, WITH ABT-072 OR ABT-333) WITH THE HELP OF DAA FOR USE WHEN TREATING HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
RU2477478C1 (en) * 2011-11-23 2013-03-10 Олег Владимирович Князев Method of assessing clinical effectiveness in inflammatory intestinal diseases
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses

Also Published As

Publication number Publication date
RU2348412C1 (en) 2009-03-10

Similar Documents

Publication Publication Date Title
Ferenci et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy
RU2007120643A (en) METHOD FOR PREVENTION OF RECURRENCE OF CHRONIC VIRAL HEPATITIS AFTER ACHIEVEMENT OF VIROLOGICAL REMISSION
RU2365372C2 (en) Cyclic protein tyrosine kinase inhibitors
RU2007132181A (en) ANTI-CANCER MEDICINE CONTAINING α, α, α-TRIFTORTIMIDINE AND A THIMIDINFOSPHORILYLASE INHIBITOR
ATE430574T1 (en) HERBAL-BASED MEDICATION FOR THE TREATMENT OF HEPATITIS C
DK1750716T3 (en) Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
RU2010133489A (en) USE OF GAMMA SECRETASE INHIBITORS FOR TREATMENT OF CANCER
RU2014122154A (en) COMPOSITIONS SUITABLE FOR THE TREATMENT OF VIRAL DISEASES
RU2010138887A (en) TREATMENT OF MALIGNANT NEW FORMATION USING VIRUSES AND CAMPTOTECINS
Shimizu et al. Hypophosphatemia in patients with hepatitis B virus infection undergoing long‐term adefovir dipivoxil therapy
RU2009101026A (en) APPLICATION OF THYMOSINE-ALPHA-1 FOR PRODUCING A MEDICINE FOR TREATING MALIGNANT MELANOMA IN STAGE IV
EA200600377A1 (en) NEW COMPOSITION
RU2010101634A (en) METHOD FOR OPTIMIZING TREATMENT OF CHRONIC MYELOLEukOSIS BY ABI TRIROZINKINASE INHIBITORS
RU2005134430A (en) METHOD FOR BASIC TREATMENT OF CHRONIC VIRAL HEPATITIS C
RU2013120345A (en) NEW METHODS FOR TREATING INFECTIONS CAUSED BY HEPATITIS C VIRUS
Kim et al. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
WO2017177515A1 (en) Application of 4-hydroxy salicylanilide in preparation of anti-myeloma or anti-lymphoma drugs
RU2008109649A (en) PEG-IFNα and Ribavirin for the Treatment of Hepatitis B Virus
CN100344284C (en) Use of Abidol in preparing medicines for treating and preventing SARS virus
WO2022019742A1 (en) Pharmaceutical package for preventing and/or treating covid-19 disease and use of same
Verhaz et al. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir±Dasabuvir Regimen in Haemodialysis Patients With Hepatitis C Virus Infection: A Case Series
CN114515338B (en) Pharmaceutical composition for treating viral hepatitis
Arora Erlotinib-induced Hepatotoxicity—Clinical Presentation and Successful Management: A Case Report
RU2013148539A (en) ALISPORIVIR FOR TREATMENT OF HEPATITIS C VIRUS INFECTION
Verhaz et al. Učinkovitost i sigurnost kombinacije ombitasvir/paritaprevir/ritonavir±dasabuvir u bolesnika na hemodijalizi s infekcijom virusom hepatitisa C: prikaz serije bolesnika

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090602